[1] Adams LA, Lindor KD, Angulo PF, et al. The prevalence of autoantibodies and autoimmune hepatitis in patients with nonalcoholic fatty liver disease. Am J Gastroenterol, 2004, 99: 1316-1320.
[2] Yatsuji S, Hashimoto E, Kaneda H, et al. Diagnosing autoimmune hepatitis in nonalcoholic fatty liver disease: is the International Autoimmune Hepatitis Group scoring system useful. J Gastroenterol, 2005, 40: 1130-1138.
[3] Loria P, Lonardo A, Leonardi F, et al. Non-organ-specific autoantibodies in nonalcoholic fatty liver disease: prevalence and correlates. Dig Dis Sci, 2003, 48: 2173-2181.
[4] Wang QX, Jiang WJ, Miao Q, et al. Clinical and histological features of autoantibody-negative autoimmune hepatitis in Chinese patients: a single center experience. J Dig Dis, 2013, 14: 175-180.
[5] Matsumoto T, Yamasaki S, Arakawa A, et al. Exposure to a high total dosage of glucocorticoids produces non-alcoholic steatohepatits. Pathology International, 2007, 57: 388-389.
[6] Tarantino G, Finelli C. Pathogenesis of hepatic steatosis: the link between hypercortisolism and non-alcoholic fatty liver disease. World J Gastroenterol, 2013, 19(40): 6735-6743.
[7] Younossi ZM, Marchesini G, Pinto-Cortez H, et al. Epidemiology of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis: implications for liver trans-plantation. Transplantation, 2019, 103: 22-27.
[8] De Luca-Johnson J, Wangensteen KJ, Hanson J, et al. Natural history of patients presenting with autoimmune hepatitis and coincident nonalcoholic fatty liver disease. Dig Dis Sci, 2016, 61: 2710-2720.
[9] Suzuki A, Diehl AM. Nonalcoholic steatohepatitis. Annu Rev Med, 2017, 68: 85-98.
[10] Tsuneyama K, Baba H, Kikuchi K, et al. Autoimmune features in metabolic liver disease: a single-center experience and review of the literature. Clin Rev Allergy Immunol, 2013, 45:143-148.
[11] Takahashi A, Arinaga-Hino T, Ohira H, et al. Nonalcoholic fatty liver disease in patients with autoimmune hepatitis. JGH Open, 2018, 2: 54-58.
[12] Trivedi PJ, Hubscher SG, Heneghan M, et al. Grand round: Autoimmune hepatitis. J Hepatol, 2019, 70: 773-784.
[13] Brown GT, Kleiner DE. Histopathology of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis. Metabolism, 2016, 65(8): 1080-1086.
[14] Powell EE, Cooksley WG, Hanson R, et al. The natural history of nonalcoholic steatohepatitis: a follow-up study of forty-two patients for up to 21 years. Hepatology, 1990, 11: 74-80.
[15] Younossi Z, Anstee QM, Marietti M, et al. Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention. Nat Rev Gastroenterol Hepatol, 2018, 15(1): 11-20.
[16] Neuschwander-Tetri BA. Hepatic lipotoxicity and the pathogenesis of nonalcoholic steatohepatitis: the central role of nontriglyceride fatty acid metabolites. Hepatology, 2010, 52(2): 774-788. |
